food effect, relative bioavailability, pharmacokinetics, safety and tolerability
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
24
Maximum concentration (Cmax)
Time frame: up to 72 hours after drug administration
Area under the concentration time curve from timepoint zero extrapolated to infinity (AUC-infinity)
Time frame: up to 72 hours after drug administration
Time to Cmax (tmax)
Time frame: up to 72 hours after drug administration
Area under the concentration time curve from timepoint zero to time of last data point above limit of quantification (AUC-tz)
Time frame: up to 72 hours after drug administration
Terminal half-life (t1/2)
Time frame: up to 72 hours after drug administration
Total mean residence time (MRTtot)
Time frame: up to 72 hours after drug administration
Volume of distribution during terminal phase after oral administration (Vz/F)
Time frame: up to 72 hours after drug administration
Total clearance after oral administration (CLtot/F)
Time frame: up to 72 hours after drug administration
Number of subjects with adverse events
Time frame: up to 8 days after last drug administration
Number of subjects with clinically significant findings in vital functions
blood pressure, pulse rate, ECG
Time frame: up to 8 days after last drug administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of subjects with clinically significant findings in laboratory tests
Time frame: up to 8 days after last drug administration